Standard BioTools Inc. (LAB)
NASDAQ: LAB · IEX Real-Time Price · USD
2.440
+0.080 (3.39%)
Apr 26, 2024, 4:00 PM EDT - Market closed
Standard BioTools Revenue
In the year 2023, Standard BioTools had annual revenue of $106.34M with 8.57% growth. Revenue in the quarter ending December 31, 2023 was $28.19M with 4.32% year-over-year growth.
Revenue (ttm)
$106.34M
Revenue Growth
+8.57%
P/S Ratio
8.79
Revenue / Employee
$199,139
Employees
534
Market Cap
934.64M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 106.34M | 8.39M | 8.57% |
Dec 31, 2022 | 97.95M | -32.63M | -24.99% |
Dec 31, 2021 | 130.58M | -7.56M | -5.47% |
Dec 31, 2020 | 138.14M | 20.90M | 17.83% |
Dec 31, 2019 | 117.24M | 4.28M | 3.79% |
Dec 31, 2018 | 112.96M | 11.03M | 10.82% |
Dec 31, 2017 | 101.94M | -2.51M | -2.40% |
Dec 31, 2016 | 104.45M | -10.27M | -8.95% |
Dec 31, 2015 | 114.71M | -1.74M | -1.50% |
Dec 31, 2014 | 116.46M | 45.27M | 63.60% |
Dec 31, 2013 | 71.18M | 18.85M | 36.02% |
Dec 31, 2012 | 52.33M | 9.47M | 22.09% |
Dec 31, 2011 | 42.87M | 9.31M | 27.73% |
Dec 31, 2010 | 33.56M | 8.15M | 32.06% |
Dec 31, 2009 | 25.41M | 10.07M | 65.58% |
Dec 27, 2008 | 15.35M | 8.07M | 110.96% |
Dec 29, 2007 | 7.28M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
MiMedx Group | 321.48M |
Innoviva | 310.46M |
Simulations Plus | 64.67M |
MacroGenics | 58.75M |
Bicycle Therapeutics | 26.98M |
Liquidia | 17.49M |
Perspective Therapeutics | 1.43M |
LAB News
- 3 days ago - Standard BioTools Announces Operational Restructuring Plan to Drive Long-Term Profitable Growth - GlobeNewsWire
- 20 days ago - Standard BioTools Introduces New High-Throughput Multiplexed Whole Slide Imaging Modalities Set to Redefine the boundaries of Tissue Imaging - GlobeNewsWire
- 24 days ago - Standard BioTools Announces Multi-Year Strategic Engagement with Bristol Myers Squibb for Use of the SomaScan® Platform for Translational Medicine Research - GlobeNewsWire
- 5 weeks ago - Standard BioTools Announces Exchange of All Outstanding Series B Convertible Preferred Stock for Common Stock - GlobeNewsWire
- 2 months ago - Standard BioTools Reports Fourth Quarter and Full Year 2023 Financial Results - GlobeNewsWire
- 2 months ago - Standard BioTools to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Standard BioTools Announces Conference Call and Webcast for Fourth Quarter and Full Year 2023 Financial Results on February 28, 2024 - GlobeNewsWire
- 2 months ago - Standard BioTools and Navignostics Announce Collaboration Agreement to Advance Imaging Capabilities in Personalized Medicine - GlobeNewsWire